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Prostate cancer is the second leading cause of
cancer-related deaths in American men
(Greenlee et al. 2001). Worldwide both the
incidence and mortality rates for prostate
cancer are recently increasing, even in low-
risk populations (Hsing et al. 2000).
However, the etiology of prostate cancer
remains incompletely deﬁned. Epidemiologic
evidence indicates that cadmium, a known
human carcinogen, is a potential prostatic
carcinogen (International Agency for Cancer
Research 1993; Waalkes 2003), and rodent
studies clearly show cadmium can induce
prostate cancer (Waalkes 2003). In addition,
in vitro model systems show cadmium can
induce malignant transformation of both
human (Achanzar et al. 2001) and rodent
prostate epithelial cells (Terracio and
Nachtigal 1988). Indeed, our recent work
showed that cadmium can induce malignant
transformation of the human prostate epithe-
lial cell line (RWPE-1) (Achanzar et al.
2001) and that these cadmium-transformed
prostate epithelial (CTPE) cells acquire
apoptotic resistance concurrently with malig-
nant phenotype (Achanzar et al. 2002).
However, the exact mechanism by which
cadmium induces malignant transformation
is unclear.
Apoptosis is a form of cell suicide that
plays an important role in development and
maintenance of tissue homeostasis in multi-
cellular organisms (Shivapurkar et al. 2003).
Apoptosis also plays an essential role in the
elimination of mutated or transformed cells
from the body (Shivapurkar et al. 2003).
Disruption of apoptosis plays a major role in
tumor formation and malignant progression
(Lowe and Lin 2000). In fact, acquired resis-
tance toward apoptosis is a hallmark of most
types of cancer (Hanahan and Weinberg
2000). Tumor cells and their precursors have
multiple mechanisms to escape or avoid
apoptosis that favor survival. The expansion
of a tumor cell population is determined not
only by the rate of cell proliferation but also
by the rate of cell apoptosis. Tumor growth
thus depends on the balance between cell
proliferation and apoptosis. Therefore,
acquired resistance to apoptosis could have
important implications in both tumor initia-
tion and progression.
Mitogen-activated protein kinases
(MAPKs) comprise a family of serine/threonine
phosphorylating proteins that mediate the
signal transduction pathways from a variety
of extracellular signals to regulate the expres-
sion of specific genes (Qu et al. 2002; Xia
et al. 1995). The extracellular signal-regulated
kinases (ERKs) typically transduce growth
factor signals that cause cell differentiation or
proliferation. Stress signals activate the c-Jun
NH2-terminal kinase (JNK) and p38 path-
ways to produce stress response, growth
arrest, and apoptosis. These MAPKs are acti-
vated by the dual phosphorylation of speciﬁc
tyrosine and threonine residues, which is per-
formed by regulatory kinases upstream in the
signaling cascade. Although activation of
JNK and p38 MAPK pathways has been asso-
ciated with induction of apoptosis (Xia et al.
1995), the precise mechanisms involved in
the JNK-induced apoptotic response remain
to be determined.
Three subfamilies of Bcl-2 [Gene ID:
24224; National Center for Biotechnology
Information (NCBI) 2007) proteins have
been identiﬁed to play important roles in the
apoptotic response. Of these subfamily mem-
bers, the Bcl-2 subfamily functions to inhibit
apoptosis, whereas the Bax (Gene ID: 12028;
NCBI 2007) and BH3 subfamilies tend to
promote apoptosis (Gross et al. 1999). Bcl-2
is an intracellular membrane-associated pro-
tein that can prevent cell death induced by a
variety of apoptotic stimuli (Park et al. 1997).
It has been demonstrated that the Bax sub-
family is essential for apoptotic signal trans-
duction by JNK (Frisch et al. 1996; Park
et al. 1996, 1997). The JNK signaling path-
way is required for stress-induced release of
mitochondrial cytochrome c and apoptosis
(Lei et al. 2002). 
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BACKGROUND: We have recently shown that cadmium can induce malignant transformation of the
human prostate epithelial cell line (RWPE-1) and that these cadmium-transformed prostate epithe-
lial (CTPE) cells acquire apoptotic resistance concurrently with malignant phenotype.
OBJECTIVE: The present study was designed to deﬁne the mechanism of acquired apoptotic resis-
tance in CTPE cells. 
METHODS: Various molecular events associated with apoptosis were assessed in control and CTPE
cells that were obtained after 8 weeks of continuous cadmium exposure.
RESULTS: Compared with control, CTPE cells showed a generalized resistance to apoptosis induced
by cadmium, cisplatin, or etoposide. Signal-regulated mitogen-activated protein kinases, extracellu-
lar signal-regulated kinases 1 and 2, c-Jun N-terminal kinases (JNK1 and JNK2), and p38 were
phosphorylated in a cadmium concentration-dependent fashion in CTPE and control cells.
However, phosphorylated JNK1/2 levels and JNK kinase activity were much lower in CTPE cells.
The pro-apoptotic gene Bax showed lower transcript and protein levels, whereas the anti-apoptotic
gene Bcl-2 showed higher levels in CTPE cells. The ratio of Bcl-2/Bax, a key determinant in apop-
totic commitment, increased more than 4-fold in CTPE cells. In Bcl-2–transfected PT-67 cells,
phosphorylated JNK1/2 levels were much lower after apoptogenic stimulus, and apoptosis induced
by cadmium or etoposide was reduced compared with control. Mutation of tyrosine to serine at the
21st amino acid of the Bcl-2 protein BH4 domain resulted in a loss both of suppression of JNK1/2
phosphorylation and its anti-apoptotic function. 
CONCLUSIONS: CTPE cells become resistant to apoptosis during malignant transformation, and dis-
ruption of the JNK pathway and Bcl-2 overexpression play important roles in this resistance. Bcl-2
BH4 domain is required for modulating JNK phosphorylation and anti-apoptotic function. 
KEY WORDS: apoptosis, Bcl-2, cadmium, JNK, malignant transformation. Environ Health Perspect
115:1094–1100 (2007). doi:10.1289/ehp.10075 available via http://dx.doi.org/ [Online 5 April 2007]The purpose of the present study was to
deﬁne the mechanisms of apoptotic resistance
and any concurrent alterations in signal trans-
duction pathways in cadmium-induced
malignant transformation using our estab-
lished in vitro human prostate epithelial car-
cinogenesis cell model system. Using this
system, we found that cadmium-transformed
cells acquired tolerance to acute cadmium
cytotoxicity and became highly resistant to
chemically induced apoptosis. This acquired
apoptotic resistance in cadmium-transformed
cells appeared to be due to overexpression of
Bcl-2, which blocked the activation of the
JNK signaling pathway by various apoptotic
stresses. 
Materials and Methods
Chemicals and reagents. Cadmium chloride
(CdCl2), etoposide, cisplatin, chloroform, iso-
propanol, formaldehyde, and ethidium bro-
mide were purchased from Sigma Chemical
Co. (St. Louis, MO). A nonradioactive cell
proliferation assay kit was obtained from
Promega (Madison, WI). 
Cell line and treatment. The development
of the human nontumorigenic parental
RWPE-1 cell line, used as the control in this
work, and the derivation of the cadmium-
transformed prostate epithelial cell line are
described in detail elsewhere (Achanzar et al.
2001; Bello et al. 1997; Webber et al. 2001).
Although immortalized, RWPE-1 cells have
retained properties exhibited by normal
prostate epithelium in vivo. The CTPE cell
line was developed by chronic cadmium expo-
sure of the RWPE-1 cell line as previously
described, and CTPE cells form aggressive,
prostate carcinoma-like tumors upon inocula-
tion into nude mice (Achanzar et al. 2001).
The observed malignant transformation in
CTPE cells is not reversible after removal from
cadmium. To deﬁne steady-state events and to
prevent acute phase effects of cadmium, cells
were placed in cadmium-free media for 2 or
more weeks before the assessment of experi-
ments. Control and CTPE cells were grown in
keratinocyte serum-free medium (KSFM) con-
taining 50 μg/mL bovine pituitary extract
(BPE), 5 ng/mL epidermal growth factor
(EGF), and 1 × antibiotic/antimycotic mixture
(10,000 U/mL penicillin G sodium,
10,000 μg/mL streptomycin sulfate, 25 μg/mL
amphotericin B). Cultures were incubated at
37°C in a humidiﬁed atmosphere containing
5% CO2. Cells were passed weekly. 
Establishing Bcl-2 producing cell line.
Murine Bcl-2 from pUSEamp-Bcl2 (Upstate
Biotechnologies, Lake Placid, NY) was sub-
cloned into pLNCX2 (OriGene Technologies,
Rockville, MD) as an 816-bp HindIII-XbaI
fragment. Bcl-2 expression was under the con-
trol of the cytomegalovirus promoter. A
Quick-change site-directed mutagenesis kit
(Stratagene, La Jolla, CA) was used to replace
the A nucleotide with a C in the coding
sequence, leading to the substitution of a serine
for a tyrosine at the 21st amino acid in the pro-
tein sequence. Mutagenesis forward and reverse
primers used were 5´-ATGAAGTACATA
CATTCTAAGCTGTCACAGAGG-3 and
5´-TCTGTGACAGCTTAGAATGTATG
TACTTCATC-3´, respectively. The sequence-
verified wild-type Bcl-2, mutated Bcl-2, and
pLNCX2 empty vector plasmid were trans-
fected separately into the BD RetroPACK
PT-67 (NIH 3T3) cell line. After 10–14 days
of growth (G418 selection, 750 μg/mL), large
visible clones were isolated and transferred to
individual dishes (Huang et al. 1997). Clones
with high expression of Bcl-2 protein or
mutant Bcl-2, termed PT67-Bcl-2 and
PT67-Bcl2Y21S, were maintained for further
analysis. The level of the endogenous Bcl-2 in
PT67-Vector was too low to be detected. All
cell lines were cultured in Dulbecco’s modiﬁed
Eagle’s media containing 10% fetal bovine
serum, 100 μg/mL streptomycin sulfate, and
100 U/mL penicillin G sodium.
Cell proliferation. We used the Promega
Cell Titer 96 Non-Radioactive Cell
Proliferation Assay kit (Promega) to determine
acute cytotoxicity of cadmium. This assay
measures the amount of formazan produced
by metabolic conversion of Owen’s reagent
[3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt, MTS] by dehydroge-
nase enzymes found in the mitochondria of
metabolically active cells. The quantity of for-
mazan product, as measured by absorbance at
490 nm, is directly proportional to the num-
ber of living cells. A minimum of four repli-
cates of 10,000 cells per well were plated in
96-well plates and allowed to adhere to the
plate for 24 hr, at which time the media was
removed and replaced with fresh media con-
taining the cadmium. Cells were then incu-
bated for an additional 24 hr and cell viability
was determined (Qu et al. 2001, 2005). We
determined the LC50 (median lethal concen-
tration) values by analyzing the linear portion
of the metabolic integrity curves and comparing
between different cells. 
Determination of apoptosis by ﬂow cytom-
etry. Detection of phosphatidylserine on the
outer plasma membrane of apoptotic cells was
performed using Annexin V and propidium
iodide according to the manufacturer’s recom-
mendations (Trevigen, Inc. Gaithersburg,
MD). For each sample, 10,000 cells were
examined by flow cytometry using a Becton
Dickinson FACSort (Becton Dickinson,
Franklin Lakes, NJ). The percent of apoptotic
cells was determined by analysis of the dot
plots using CellQuest software (Qu et al.
2002). 
Western blot analysis. After cells were
grown to 70–80% confluence, they were
placed in supplement-free medium for 24 hr.
Cells were then washed with ice-cold phos-
phate-buffered saline, and scraped into cell
lysis buffer containing 50 mM HEPES (pH
7.5), 150 mM NaCl, 1.5 mM MgCl2, 50 mM
pyrophosphate, 1 mM sodium orthovanadate,
1 mM EGTA, 100 mM sodium fluoride,
1% Triton X-100, 10% glycerol, 10 μg/mL
leupeptin, 10 μg/mL aprotinin, and 1 mM
phenylmethylsulfonyl ﬂuoride. The cells were
incubated in lysis buffer for 30 min on ice,
sonicated, and centrifuged at 14,000 × g for
15 min. The supernatant was designated as the
cell lysate (Qu et al. 2002). Protein concentra-
tion was determined by the Bio-Rad method
(Bio-Rad, Hercules, CA). Protein samples
(20 μg) derived from the various cell prepara-
tions were subjected to sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis and
transferred onto nitrocellulose membranes.
The membranes were blocked with 5% nonfat
dry milk in Tris-buffered saline containing
0.05% Tween 20 and probed with various
antibodies. After incubation with secondary
antibodies, immunoblots were visualized with
the LumiGlo detection method purchased
from New England Biolabs (Beverly, MA). 
JNK activity assay. We determined the
enzymatic activity of JNKs using commer-
cially available kits (New England Biolabs,
Beverly, MA). Brieﬂy, cell extracts containing
Cadmium induced apoptotic resistance
Environmental Health Perspectives • VOLUME 115 | NUMBER 7 | July 2007 1095
Figure 1. CTPE cells acquire generalized resistance to apoptosis. (A) CTPE and control RWPE-1 cells were
treated with 10 or 20 µM cadmium for 24 hr. (B) CTPE and control cells were treated with etoposide
(50 µg/mL) or cisplatin (10 µM) for 24 hr. Apoptosis was determined by ﬂow cytometry using ﬂuorescent-
labeled annexin V and propidium iodide. Data represent the percent of apoptotic cells in lower right quad-
rants. Results are presented as the mean ± SE, n = 3. 
aSigniﬁcantly (p < 0.05) different from cell-line–matched untreated cells; 
bsigniﬁcantly (p < 0.05) different
from dosage-matched control cells.
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CTPE250 μg total protein were incubated overnight
at 4°C with an N-terminal c-Jun fusion pro-
tein bound to glutathione–Sepharose beads
for JNK kinase activity assay. The kinase reac-
tion was performed by adding 100 μmol/L
adenosine triphosphate to the suspension.
Phosphorylation of c-Jun was measured by
Western blot analysis with a phospho-speciﬁc
c-Jun antibody that speciﬁcally detects Ser63-
phosphorylated c-Jun, a site important for
c-Jun-dependent transcriptional activity (Qu
et al. 2002).
Quantitative real-time RT-PCR analysis.
Total RNA was isolated using TRIzol
(GIBCO/BRL Life Technologies, Bethesda,
MD), then subjected to DNase digestion by
using a RNase-Free DNase set (Qiagen,
Valencia, CA) followed by the cleanup using a
RNeasy Mini kit (Qiagen). The resultant
DNA-free RNA was quantitated by ultraviolet
spectroscopy at 260 nm and stored in RNase-
free H2O at –70°C. Quantitative real-time
RT-PCR was conducted as described previ-
ously (Waalkes et al. 2004). Brieﬂy, total RNA
from each sample was reverse transcribed with
murine leukemia virus (MuLV) reverse tran-
scriptase (Applied Biosystems, Foster City,
CA) and oligo-d(T) primers. The SYBR
Green PCR Kit (Applied Biosystems) was
used for quantitative real-time RT-PCR analy-
sis. The primers were designed using Primer
Express software (Applied Biosystems) and are
listed here: Bax, Forward CATGGAGCT
GCAGAGGATGAT; Reverse GTCAGCT
GCCACTCGGAAAA. Bcl-2, Forward TC
CCTCGCTGCACAAATACTC; Reverse
TTCTGCCCCTGCCAAATCT. β-actin,
Forward ACTGGAACGGTGAAGGTGA
CA; Reverse ATGGCAAGGGACTTCCTG
TAAC. Relative differences in gene expression
between groups were expressed using cycle
time (Ct) values. These values were first
normalized with that of β-actin in the same
sample, and the expression in the experiment
group was expressed as a percentage of
expression in controls. Real-time ﬂuorescence
detection was carried out using a MyiQ
singleColor Real-Time PCR Detection
System (Bio-Rad).
Statistical analysis. For data expressed as
mean ± SE, Student’s t-test or analysis of vari-
ance with subsequent Dunnett’s test was used
as appropriate. Incidence data were tested by
Fisher’s exact test. Values are derived from
three or more replicates. Differences were
considered signiﬁcant at p < 0.05.
Results
Acute cytotoxicity of cadmium. Continuous
cadmium exposure for 8 or more weeks
induces malignant transformation in RWPE-1
cells, producing the tumor-forming CTPE
transformant (Achanzar et al. 2001). In the
present study, CTPE and passage-matched
RWPE-1 control cells were treated with cad-
mium for 24 hr, and cytotoxicity was meas-
ured. CTPE cells clearly acquired tolerance to
the acute toxic effects of cadmium. The LC50
value for CTPE cells exposed to cadmium was
15.5 ± 1.9 μM compared with 7.0 ± 0.5 μM
in control cells—a 2.2-fold difference reﬂect-
ing a marked reduction in sensitivity. 
CTPE cells acquire generalized resistance
to chemically induced apoptosis. To deter-
mine if acquired apoptotic resistance occurred
concurrently with cadmium-induced malig-
nant transformation, control and CTPE cells
were treated with cadmium and apoptosis was
determined by flow cytometry. Cadmium-
induced apoptosis was markedly reduced in
CTPE cells compared with control cells
(Figure 1A). These results indicate that after
transformation has occurred, cells acquired a
marked resistance to apoptosis induced by
cadmium. Furthermore, to detect whether the
CTPE cells possessed generalized apoptotic
resistance, control and CTPE cells were
treated with etoposide, a DNA repair inhibitor
and potent apoptogen, or cisplatin, a chemo-
therapeutic compound, for 24 hr. Analysis of
the ﬂow cytometry data revealed that CTPE
cells had about 40% fewer apoptotic cells
than control when exposed to either etopo-
side or cisplatin (Figure 1B).
Cadmium-transformed phenotype shows
reduced JNK1/2 phosphorylation and JNK1/2
kinase activity. The JNK and p38 pathways
have been implicated in the regulation of
apoptosis induced by various stimuli (Xia et al.
1995). Several recent articles have suggested
that ERK might also be involved in apoptotic
signaling (e.g., Mohr et al. 1998). To deter-
mine which signal pathway may be involved
in cadmium-induced apoptosis, cells were
acutely subjected to cadmium (0, 10, 50 or
100 μM) for 30 min. The levels of phosphory-
lated ERK1/2, JNK1/2, and p38 were deter-
mined by Western blot analysis. All three
MAPKs were phosphorylated in a cadmium
concentration-dependent fashion both in con-
trol and CTPE cells. Interestingly, the level of
phosphorylated JNK1/2 was markedly
decreased in the CTPE cells compared with
control cells (Figure 2A). The membrane used
to define the phosphorylated form was
stripped, then reprobed with antibody against
JNK that recognizes both the phosphorylated
and nonphosphorylated forms to assess total
JNK1/2. As shown in Figure 2B, no major
differences were observed in the levels of total
Qu et al.
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Figure 2. Effect of acute cadmium treatment on levels of phosphorylated JNK1/2 and JNK1/2 kinase activity in CTPE and control cells. Cells were acutely exposed
to various concentrations of cadmium for 30 min. (A) The levels of phosphorylated JNK1/2 were determined by Western blot analysis (upper panel) and were ana-
lyzed by scanning densitometry (lower panel). (B) After development, the membrane was stripped and reprobed with regular antibodies against JNK1/2 (upper
panel) and was analyzed by scanning densitometry (lower panel). (C) Cells were treated with cadmium for 30 min at the levels indicated for the concentration
response assessment or were treated with 100 µM cadmium for the time course assessment. Cell extracts were incubated overnight with c-Jun fusion protein.
Phosphorylation of c-Jun at Ser263 was measured by Western blot using phospho-c-Jun (Ser263) antibody. Results were analyzed by scanning densitometry.
Blot represents a typical result of three independent experiments. The values were standardized to untreated control as 1. Results are presented as the mean ± SE;
n = 3 experiments. 
aSigniﬁcantly (p < 0.05) different from cell-line matched untreated cells; 
bsigniﬁcantly (p < 0.05) different from dosage-matched control cells.JNK1/2. Thus, the decrease in phosphorylated
JNK represents a decrease in phosphorylation
of the native protein in transformed cells
rather than a reduction in total cellular JNK
protein. The levels of both phosphorylated
ERK1/2 and p38 did not show any signiﬁcant
differences between control and CTPE cells
(data not shown). Dual phosphorylation of
JNKs at Thr183/Tyr185 is essential for
kinase activity and phosphorylation at these
sites is an excellent marker of JNK activity.
To conﬁrm JNK activation, an in vitro kinase
assay was performed using a c-Jun N-terminal
fusion protein as the substrate. After acute
cadmium exposure, JNK kinase activation
was markedly reduced in CTPE cells com-
pared with control cells in both the concen-
tration–response and time-course analysis
(Figure 2C). The levels of phosphorylation of
JNK determined by using the phospho-
specific antibody were thus consistent with
the kinase activity of JNK in cell extracts. 
Effect of Ro318220 on JNK1/2 kinase
activity and apoptosis. The compound
Ro318220 (Ro) is a strong activator of JNK
(Beltman et al. 1996; Sandau et al. 1999).
Thus, studies were designed to determine if
Ro318220 could bypass the blockage of JNK
kinase activity in CTPE cells. Cells were pre-
treated with Ro318220 (10 μM, 30 min) fol-
lowed by acute cadmium exposure (100 μM,
30 min), and an in vitro kinase assay was per-
formed using a c-Jun N-terminal fusion pro-
tein as the substrate. As shown in Figure 3A,
after cadmium treatment JNK kinase activity
was much lower in CTPE cells compared
with control, confirming early experiments.
However, pretreatment with Ro318220
before cadmium effectively bypassed this
block in JNK activity, bringing JNK kinase
activity in CTPE cells to control levels. EGF,
used as a positive control for stimulating JNK
activity, was much less effective in CTPE
than control cells. These results suggest that
the activation of the JNK pathway is per-
turbed in CTPE cells, speciﬁcally at the point
of JNK phosphorylation. To conﬁrm that the
effects of Ro318220 depend JNK1/2 activa-
tion and are not due to protein kinase C
(PKC) inhibition, similar experiments were
performed with staurosporine (40 nM) and
GF109203 (2.5 mM), two well-known PKC
inhibitors (Beltman et al. 1996; Sandau et al.
1999). In contrast to the effects of Ro318220
on JNK kinase activation, both staurosporine
and GF109203 did not affect JNK kinase
activation in either control or CTPE cells. To
determine if JNK activation through
Ro318220 could bypass the apoptotic block
seen after cadmium-induced transformation,
cells were pretreated with Ro318220 before
cadmium treatment and apoptosis was
assessed (Figure 3B). Cadmium was again
markedly less effective in inducing apoptosis
in CTPE cells compared with control. The
addition of Ro318220 before acute cadmium
treatment significantly increased apoptotic
rate between 2.6- and 3.7-fold in CTPE cells.
Expression of pro- and anti-apoptotic
genes. Bax is an important pro-apoptotic pro-
tein and Bcl-2 is an important anti-apoptotic
protein. It has been reported that multiple sig-
nal transduction pathways, including JNK, are
capable of modifying Bcl-2 family members to
reset susceptibility to apoptosis (Kharbanda
et al. 2000; Yamamoto et al. 1999). Thus, the
transcriptional levels of Bcl-2 and Bax in
CTPE and control were determined. Both
Bcl-2 and Bax transcript levels were signifi-
cantly different in CTPE cells compared with
control cells. The ratio of Bcl-2/Bax transcripts
was increased over 2-fold in CTPE cells com-
pared with control cells (Figure 4A). These
results were conﬁrmed by Western blot analy-
sis (Figure 4B). The levels of Bcl-2 protein
were substantially increased (~ 5-fold),
whereas the level of Bax protein was markedly
decreased (~ 2-fold) in the CTPE cells. The
densitometric analysis showed that the ratio of
Bcl-2/Bax, which is though to be an impor-
tant determinant in dictating apoptosis, was
significantly increased (more than 4-fold) in
CTPE cells (Figure 4C), a ﬁnding indicative
of reduced apoptosis. 
Bcl-2 suppresses the JNK1/2 phosphoryla-
tion and apoptosis induced by cadmium. To
help define any possible interplay between
Bcl-2 and JNK1/2, Bcl-2 was transfected via a
murine expression vector into PT-67 cells.
Expression of Bcl-2 protein was detected sta-
bly in Bcl-2–transfected cells, but not in con-
trol cells (Figure 5A). Next, vector control
and Bcl-2–transfected cells were treated with
cadmium (5 μM) or etoposide (50 μg/mL)
for 24 hr, and apoptosis was determined.
Cadmium-induced apoptosis was markedly
reduced in Bcl-2–transfected cells compared
Cadmium induced apoptotic resistance
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Figure 4. Effect of transformation on the ratio of
Bcl-2/Bax at transcription and protein levels.
(A) Real-time PCR of Bcl-2 and Bax was performed
in triplicate, the results were normalized to β-actin
and are expressed as a ratio. (B) Western blot
analysis of protein derived from CTPE and control
cells using specific Bcl-2, Bax, and β-actin anti-
bodies. Blot shown represents a typical result of
four independent experiments. (C) The levels of
Bcl-2, Bax, and β-actin protein were analyzed by
scanning densitometry and used to calculate the
ratio of Bcl-2/Bax based on β-actin. (B) indicates a
signiﬁcant (p < 0.05) difference from control cells. 
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Figure 3. Effect of Ro318220 on cadmium-induced
JNK1/2 kinase activity and apoptosis. (A) CTPE and
control cells were pretreated with 10 µM Ro318220
(Ro), an activator of JNK, for 30 min, followed by
cadmium (100 µM) treatment for 30 min. One group
of each cell type was also treated with EGF
(10 ng/mL) for 5 min. Activity of JNK1/2 kinase was
then measured as described in Figure 2C (upper
panel). Results were analyzed by scanning densito-
metry (lower panel). Blot represents one of three
independent experiments. (B) CTPE and control cells
were pretreated with 10 µM Ro318220 for 30 min, fol-
lowed by cadmium (5 or 10 µM) treatment for 24 hr.
Apoptosis was determined by ﬂow cytometry. Data
are given as the proportion (%) of the total number
of cells gated that are apoptotic cells. Results are
presented as the mean ± SE, n = 3 experiments. 
aSignificantly (p < 0.05) different from cell-line matched
untreated cells; bSignificantly (p < 0.05) different from
dosage-matched control cells.with vector control cells (Figure 5B).
Moreover, etoposide-induced apoptosis was
also signiﬁcantly decreased in Bcl-2–express-
ing cells. Furthermore, the effect of acute
cadmium treatment on JNK1/2 phosphory-
lation in either vector control or Bcl-2–trans-
fected cells was examined. As expected, the
level of phosphorylated JNK1/2 was
markedly decreased in Bcl-2–transfected cells
(Figure 5C). The membrane used to define
the phosphorylated form was stripped, then
reprobed with antibody against JNK that
recognizes both the phosphorylated and non-
phosphorylated forms to assess total JNK1/2.
No major differences were observed in the
levels of total JNK1/2 (Figure 5D). Taken
together, these data suggest that Bcl-2 might
modulate the JNK signaling cascade, which
in turn prevents cadmium-induced apoptosis. 
To determine whether the BH4 region of
Bcl-2 is essential for its anti-apoptotic func-
tion, Bcl-2 Y21 mutant cell line was estab-
lished by site-specific mutagenesis, which
replaced the tyrosine with a serine at the 21st
amino acid of Bcl-2 (Huang et al. 1997).
Vector control, Bcl-2–transfected, and Bcl-2
Y21 mutant cells were treated with cadmium
or etoposide for 24 hr, and apoptosis was
determined by flow cytometry. Both cad-
mium- and etoposide-induced apoptosis were
markedly reduced in Bcl-2–transfected cells
but restored largely in Bcl-2 Y21 mutant cells
(Figure 6A). Furthermore, the effect of acute
cadmium treatment on JNK1/2 phosphoryla-
tion in vector control, Bcl-2–transfected, and
Bcl-2 Y21 mutant cells was examined. Most
interestingly, the level of phosphorylated
JNK1/2 was markedly decreased in Bcl-2–
transfected cells but partially restored in Bcl-2
Y21 mutant cells (Figure 6B). The membrane
used to define the phosphorylated form was
stripped, then reprobed with antibody against
JNK that recognizes both the phosphorylated
and nonphosphorylated forms to assess total
JNK1/2. No major differences were observed
in the levels of total JNK1/2 (Figure 6C).
These data indicate that the Bcl-2 BH4
domain is involved in modulating JNK phos-
phorylation and its anti-apoptotic function.
Discussion
It is unclear if cadmium acts as a carcinogen
through genotoxic or epigenetic mechanisms.
Whatever the basis, an important mechanism
could be the disruption of signal transduc-
tion pathways resulting in aberrant cell accu-
mulation. In this regard, the present study
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aSignificantly (p < 0.05) different from untreated control;
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aSigniﬁcantly (p < 0.05) different from untreated
control; 
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as the mean ± SE, n = 3 experiments.
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aSigniﬁcantly (p < 0.05) different from appropriate untreated control; 
bsigniﬁcantly (p < 0.05) different from appropriate dosage-matched control. demonstrates that chronic cadmium-trans-
formed prostate epithelial cells acquire general-
ized tolerance to chemically induced apoptosis.
Disruption of apoptosis plays a major role in
tumor formation and malignant progression.
The activation of apoptosis is regulated by
many different signals that originate from both
intracellular and the extracellular sites
(Vasilevskaya and O’Dwyer 2003). For exam-
ple, the JNK signaling pathway has been impli-
cated in the apoptotic response of cells exposed
to stress. Several studies indicate that genotoxic
stress induces translocation of stress-activated
protein kinase (SAPK)/JNK to mitochondria
(Kharbanda et al. 2000). Mitochondria are
influenced by pro-apoptotic signal transduc-
tion through the JNK pathway, and the
absence of JNK caused a defect in the mito-
chondrial death-signaling pathway, including
the failure to release cytochrome c (Tournier
et al. 2000). Therefore, JNK is required
for stress-induced activation of the cyto-
chrome c–mediated death pathway (Tournier
et al. 2000). The results of the present study
clearly demonstrate that JNK activation is per-
turbed in cadmium-transformed cells and that
Ro318220, a strong activator of JNK, circum-
vents this apoptotic resistance. Therefore, cad-
mium-induced resistance to apoptosis appears
to involve the speciﬁc suppression of the JNK
pathways, which increases cell survival and
decreases apoptosis (Vivo et al. 2003). In this
regard, our prior work showed that after arsen-
ite induced malignant transformation in vitro,
generalized resistance to apoptosis develops,
likely due to perturbation of the JNK pathway
(Qu et al. 2002). In fact, these results are con-
sistent with several reports that the stimulation
of JNK is a prerequisite for cell apoptosis
under various conditions, and a blockade of
JNK activation results in the prevention of
apoptosis (Verheij et al. 1996; Vivo et al. 2003;
Xia et al. 1995). This blockade of apoptosis
could be a key factor in cadmium carcinogenesis.
There are many possible targets of the JNK
signaling pathway that may affect the mito-
chondria, including members of the Bcl-2
group of apoptotic regulatory proteins
(Tournier et al. 2000). It has been reported
that the anti-apoptotic protein Bcl-2 is
phosphorylated and inactivated by JNK
(Yamamoto et al. 1999). Bcl-2 disrupts a sig-
naling cascade to the c-Jun N-terminal kinase
activation induced by the apoptotic stresses
(Park et al. 1997). However, the exact molecu-
lar mechanisms by which Bcl-2 prevents cell
death remain unknown. It has been proposed
that Bcl-2 might suppress cell death by modu-
lating intracellular signaling cascades associated
with apoptosis (Park et al. 1997). The cloning
and characterization of the Bcl-2 oncogene
established the importance of apoptosis in
tumor development (Lowe and Lin 2000).
For example, Bcl-2 promotes cell survival by
blocking programmed cell death and disrupt-
ing normal proliferation (Hockenbery et al.
1990; McDonnell et al. 1989). It is recognized
that Bcl-2 is expressed in a variety of human
tumors. In particular, Bcl-2 overexpression is
associated with prostate carcinoma (Herrmann
et al. 1997). Conversely, Bax is a death pro-
moter that is inactivated in certain types of
cancer and plays critical roles in the initiation
and execution of the apoptotic program
(Putcha et al. 2003). The present study
demonstrates that Bax protein levels were
greatly reduced, and anti-apoptotic protein
Bcl-2 expression markedly increased in CTPE
cells as compared with RWPE-1 cells.
Bcl-2:Bax ratio was approximately four times
higher in CTPE cells than in control cells,
which is consistent with perturbed apoptosis.
The suppression of cell death could favor the
development and progression of neoplasms by
providing a selective survival advantage for
transformed cells. Furthermore, upon investi-
gation of a possible interplay between Bcl-2
and JNK1/2, we found the level of phos-
phorylated JNK1/2 was markedly decreased
in a cadmium dose-dependent manner in
Bcl-2–transfected cells. Also, cadmium- or
etoposide-induced apoptosis was markedly
reduced in Bcl-2–expressing cells compared
with vector control cells. These data indicate
that the intracellular signaling pathway for
JNK stimulation is defective in Bcl-2–overex-
pressing cells, and Bcl-2 prevents both JNK
signaling and cell death induced by various
apoptotic stresses. The JNK signaling pathway
might be downstream from the target of Bcl-2
action. Further study will be required to deﬁne
precisely the interplay between JNK and Bcl-2. 
The anti-apoptotic members of the Bcl-2
family contain four homology domains, BH1,
BH2, BH3, and BH4 (Janumyan et al. 2003).
The five most closely related mammalian
homologues are Bcl-2, Bcl-xL (Gene ID:
12048), Bcl-w (Gene ID: 12050), and Bax and
Bak (Gene ID: 12018) (NCBI 2007).
However, only the first three contain the
N-terminal BH4 domain and inhibit apoptosis
(Huang et al. 1998). BH1 and BH2 of Bax are
critical for promoting cell survival, but Bax
does not contain a region functionally equiva-
lent to BH4 of Bcl-2 (Huang et al. 1998). To
determine whether the BH4 region of Bcl-2 is
essential for its anti-apoptotic function and
regulation with JNK signal transduction path-
way, we established a Bcl-2 Y21 mutant cell
line by site-speciﬁc mutagenesis, which replaces
the tyrosine with a serine at the 21st amino
acid. Our results showed that Bcl-2–transfected
cells were resistant to cadmium- or etoposide-
induced apoptosis. Mutation of tyrosine at the
21st amino acid to serine resulted in loss of
anti-apoptotic function that resulted in Bcl-2
Y21 mutant cells becoming as sensitive as
vector control cells to apoptosis. Thus, the
N-terminal BH4 domain is essential for the
anti-apoptotic activity of Bcl-2, confirming
previous published reports (Huang et al. 1998;
Hunter et al. 1996). Most interestingly, our
study showed that the level of phosphorylated
JNK1/2 was markedly lower in Bcl-2–trans-
fected cells than in vector control cells with
cadmium treatment, but partially restored in
Bcl-2 Y21 mutant cells. Taken together, these
data suggest that the Bcl-2 BH4 domain is
required for modulating JNK phosphorylation
and anti-apoptotic function.
In summary, after cadmium-induced
malignant transformation has occurred in
human prostate epithelial cells, transformed
cells acquire resistance to apoptosis. The
acquisition of apoptotic resistance appears to
be linked to an increase in the anti-apoptotic
action of Bcl-2 that perturbs the JNK signal
transduction pathway. The Bcl-2 BH4
domain is required for modulating JNK phos-
phorylation and anti-apoptotic function. This
acquired self-resistance to apoptosis may play
an important role in cadmium-induced
tumor initiation and progression.
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